Aditxt (Aditxt) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is Aditxt Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Aditxt is: No Data: Cannot be evaluated.

Competitive Comparison of Aditxt's Risk Assessment

For the Biotechnology subindustry, Aditxt's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aditxt's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aditxt's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Aditxt's Risk Assessment falls into.

Aditxt (NAS:ADTX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Aditxt Risk Assessment Related Terms

Thank you for viewing the detailed overview of Aditxt's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Aditxt (Aditxt) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aditxt Inc (NAS:ADTX) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

737 North Fifth Street, Suite 200, Richmond, VA, USA, 23219

Website

https://www.aditxt.com

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes a tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.

Executives

Charles Athle Nelson	director	11-F, BUILDING 12, SUNKING PLAZA, GAOJIAO ROAD, HANGZHOU, ZHEJIANG F4 311122
Bnp Paribas Securities Corp	10 percent owner	787 SEVENTH AVE, NEW YORK NY 10019
Matthew Shatzkes	officer: Chief Legal Officer and GC	737 N. FIFTH STREET, SUITE 200, RICHMOND VA 23219
Lauren Chung	director	1620 BEACON STREET, OXNARD CA 93033
Thomas J Farley	officer: PRINCIPAL ACCOUNTING OFFICER	2569 WYANDOTTE ST., SUITE 101, MOUNTAIN VIEW CA 94043
Jeffrey W. Runge	director	C/O PHARMATHENE, INC., ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
Rowena Albanna	officer: CHIEF OPERATING OFFICER	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Rosland Fisher Mcleod	director	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Pankovcin Corinne	officer: CHIEF FINANCIAL OFFICER	BUSINESS DEVELOPMENT CORP OF AMERICA, 405 PARK AVENUE, 14TH FLOOR, NEW YORK NY 10022
Laura E Anthony	director	LAURA ANTHONY, 120 S. OLIVE AVE, WEST PALM BEACH FL 33401
Namvar Kiaie	director	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Brian Michael Brady	director	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Amro A. Albanna	director, officer: CHIEF EXECUTIVE OFFICER	871 MARLBOROUGH AVENUE, SUITE 100, RIVERSIDE CA 92507
Shahrokh Shabahang	director, officer: CHIEF INNOVATION OFFICER	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354